{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:07:37Z","timestamp":1793196457373,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00740-x","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T13:45:35Z","timestamp":1737207935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A lyophilised formulation of chimpanzee adenovirus vector for long-term stability outside the deep-freeze cold chain"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1254-5343","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Mathot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwige","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6183-387X","authenticated-orcid":false,"given":"Bernard G.","family":"Francq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-5395","authenticated-orcid":false,"given":"Erwan","family":"Bourl\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"740_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2471\/BLT.13.123471","volume":"92","author":"P Lydon","year":"2014","unstructured":"Lydon, P. et al. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bull. World Health Organ 92, 86\u201392 (2014).","journal-title":"Bull. World Health Organ"},{"key":"740_CR2","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.vaccine.2016.08.045","volume":"35","author":"A Ashok","year":"2017","unstructured":"Ashok, A., Brison, M. & LeTallec, Y. Improving cold chain systems: Challenges and solutions. Vaccine 35, 2217\u20132223 (2017).","journal-title":"Vaccine"},{"key":"740_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13520","volume":"7","author":"M Pelliccia","year":"2016","unstructured":"Pelliccia, M. et al. Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months. Nat. Commun. 7, 13520 (2016).","journal-title":"Nat. Commun."},{"key":"740_CR4","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1016\/j.vaccine.2015.08.085","volume":"33","author":"LJJ Hansen","year":"2015","unstructured":"Hansen, L. J. J., Daoussi, R., Vervaet, C., Remon, J. P. & De Beer, T. R. M. Freeze-drying of live virus vaccines: A review. Vaccine 33, 5507\u20135519 (2015).","journal-title":"Vaccine"},{"key":"740_CR5","doi-asserted-by":"publisher","first-page":"100119","DOI":"10.1016\/j.jvacx.2021.100119","volume":"9","author":"S Jarrett","year":"2021","unstructured":"Jarrett, S. et al. The importance of vaccine stockpiling to respond to epidemics and remediate global supply shortages affecting immunization: strategic challenges and risks identified by manufacturers. Vaccin. X 9, 100119 (2021).","journal-title":"Vaccin. X"},{"key":"740_CR6","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.1016\/j.vaccine.2021.10.065","volume":"39","author":"D Hosangadi","year":"2021","unstructured":"Hosangadi, D., Martin, E. K., Watson, M., Bruns, R. & Connell, N. Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future. Vaccine 39, 6972\u20136974 (2021).","journal-title":"Vaccine"},{"key":"740_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1208\/s12249-021-01974-3","volume":"22","author":"K AboulFotouh","year":"2021","unstructured":"AboulFotouh, K., Cui, Z. & Williams, R. O. 3rd Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. AAPS PharmSciTech 22, 126 (2021).","journal-title":"AAPS PharmSciTech"},{"key":"740_CR8","unstructured":"Janssen-Cilag International NV. Jcovden (previously COVID-19 Vaccine Janssen): EPAR - Medicine overview. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf (2022)."},{"key":"740_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"740_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","volume":"20","author":"MD Tapia","year":"2020","unstructured":"Tapia, M. D. et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 20, 707\u2013718 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"740_CR11","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/cid\/ciz653","volume":"70","author":"P Cicconi","year":"2020","unstructured":"Cicconi, P. et al. First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. Clin. Infect. Dis. 70, 2073\u20132081 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"740_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","volume":"16","author":"O De Santis","year":"2016","unstructured":"De Santis, O. et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study. Lancet Infect. Dis. 16, 311\u2013320 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"740_CR13","doi-asserted-by":"publisher","unstructured":"Berg, A. et al. Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations. Vaccines (Basel) 9, https:\/\/doi.org\/10.3390\/vaccines9111249 (2021).","DOI":"10.3390\/vaccines9111249"},{"key":"740_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00674-2","volume":"8","author":"C Zhang","year":"2023","unstructured":"Zhang, C., Berg, A., Joe, C. C. D., Dalby, P. A. & Douglas, A. D. Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration. NPJ Vaccines 8, 85 (2023).","journal-title":"NPJ Vaccines"},{"key":"740_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijpharm.2011.12.056","volume":"427","author":"S Chen","year":"2012","unstructured":"Chen, S. et al. Investigation on formulation and preparation of adenovirus encoding human endostatin lyophilized powders. Int J. Pharm. 427, 145\u2013152 (2012).","journal-title":"Int J. Pharm."},{"key":"740_CR16","doi-asserted-by":"publisher","first-page":"e0006870","DOI":"10.1371\/journal.pntd.0006870","volume":"12","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Negl. Trop. Dis. 12, e0006870 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"740_CR17","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.vaccine.2016.03.061","volume":"34","author":"P Dulal","year":"2016","unstructured":"Dulal, P. et al. Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine 34, 2296\u20132298 (2016).","journal-title":"Vaccine"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","volume":"2","author":"R Alcock","year":"2010","unstructured":"Alcock, R. et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2, 19ra12 (2010).","journal-title":"Sci. Transl. Med"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijpharm.2016.04.067","volume":"506","author":"DA LeClair","year":"2016","unstructured":"LeClair, D. A., Cranston, E. D., Xing, Z. & Thompson, M. R. Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying. Int J. Pharm. 506, 289\u2013301 (2016).","journal-title":"Int J. Pharm."},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1016\/j.vaccine.2017.04.026","volume":"35","author":"S Afkhami","year":"2017","unstructured":"Afkhami, S. et al. Spray dried human and chimpanzee adenoviral-vectored vaccines are thermally stable and immunogenic in vivo. Vaccine 35, 2916\u20132924 (2017).","journal-title":"Vaccine"},{"key":"740_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00065-4","volume":"11","author":"P Dulal","year":"2021","unstructured":"Dulal, P. et al. Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. Sci. Rep. 11, 20877 (2021).","journal-title":"Sci. Rep."},{"key":"740_CR22","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1016\/j.vaccine.2010.04.059","volume":"28","author":"TH Jin","year":"2010","unstructured":"Jin, T. H., Tsao, E., Goudsmit, J., Dheenadhayalan, V. & Sadoff, J. Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine 28, 4369\u20134375 (2010).","journal-title":"Vaccine"},{"key":"740_CR23","doi-asserted-by":"publisher","first-page":"e67888","DOI":"10.1371\/journal.pone.0067888","volume":"8","author":"FE Pearson","year":"2013","unstructured":"Pearson, F. E. et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One 8, e67888 (2013).","journal-title":"PLoS One"},{"key":"740_CR24","unstructured":"Mathot, F. S. & Vasselle, M. EP3814511 - Formulations For Simian Adenoviral Vectors Having Enhanced Stability. (2019)"},{"key":"740_CR25","unstructured":"Bourl\u00e8s, E., Despas, O., Guillaume, D., Mathot, F. S. & Vasselle, M. WO2018138667A1 Novel Formulation for Stabilizing Adenovectors. (2018)."},{"key":"740_CR26","unstructured":"Bourl\u00e8s, E. & Mathot, F. S. WO2017013169A1 Pharmaceutical Composition Comprising an Adenoviral Vector. (2017)."},{"key":"740_CR27","unstructured":"Levet, V. E., Mathot, F. S. & Vuylsteke, B. EP3833382 - Processes and Vaccines (2019)."},{"key":"740_CR28","unstructured":"Searles, J. A. in Freeze-Drying\/Lyophilization of Pharmaceutical and Biological Products (ed L. Rey) Ch. 3, 52-81 (Taylor & Francis Group, 2010)."},{"key":"740_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0040-6031(71)85051-7","volume":"3","author":"J \u0160est\u00e1k","year":"1971","unstructured":"\u0160est\u00e1k, J. & Berggren, G. Study of the kinetics of the mechanism of solid-state reactions at increasing temperatures. Thermochim. Acta 3, 1\u201312 (1971).","journal-title":"Thermochim. Acta"},{"key":"740_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","volume":"39","author":"EM Castilow","year":"2007","unstructured":"Castilow, E. M., Olson, M. R. & Varga, S. M. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39, 225\u2013239 (2007).","journal-title":"Immunol. Res."},{"key":"740_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","volume":"35","author":"BS Graham","year":"2015","unstructured":"Graham, B. S., Modjarrad, K. & McLellan, J. S. Novel antigens for RSV vaccines. Curr. Opin. Immunol. 35, 30\u201338 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"740_CR32","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1016\/j.vaccine.2014.02.033","volume":"32","author":"M Stewart","year":"2014","unstructured":"Stewart, M., Ward, S. J. & Drew, J. Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chain. Vaccine 32, 2931\u20132938 (2014).","journal-title":"Vaccine"},{"key":"740_CR33","doi-asserted-by":"publisher","first-page":"115ra112","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4, 115ra112 (2012).","journal-title":"Sci. Transl. Med."},{"key":"740_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/10837450701212826","volume":"12","author":"VV Nesarikar","year":"2007","unstructured":"Nesarikar, V. V. & Nassar, M. N. Effect of cations and anions on glass transition temperatures in excipient solutions. Pharm. Dev. Technol. 12, 259\u2013264 (2007).","journal-title":"Pharm. Dev. Technol."},{"key":"740_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44020-w","volume":"9","author":"V Leung","year":"2019","unstructured":"Leung, V. et al. Thermal Stabilization of Viral Vaccines in Low-Cost Sugar Films. Sci. Rep. 9, 7631 (2019).","journal-title":"Sci. Rep."},{"key":"740_CR36","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1016\/j.vaccine.2021.07.002","volume":"39","author":"M Gomez","year":"2021","unstructured":"Gomez, M. et al. Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery. Vaccine 39, 5025\u20135036 (2021).","journal-title":"Vaccine"},{"key":"740_CR37","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1016\/j.vaccine.2023.04.039","volume":"41","author":"J de la Torre Arrieta","year":"2023","unstructured":"de la Torre Arrieta, J., Briceno, D., de Castro, I. G. & Roser, B. A thermostable tetanus\/diphtheria (Td) vaccine in the StablevaX pre-filled delivery system. Vaccine 41, 3413\u20133421 (2023).","journal-title":"Vaccine"},{"key":"740_CR38","doi-asserted-by":"publisher","first-page":"e17325","DOI":"10.1016\/j.heliyon.2023.e17325","volume":"9","author":"MC Archer","year":"2023","unstructured":"Archer, M. C. et al. Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine. Heliyon 9, e17325 (2023).","journal-title":"Heliyon"},{"key":"740_CR39","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/10837450.2020.1806298","volume":"25","author":"B Scutella","year":"2020","unstructured":"Scutella, B. & Bourles, E. Development of freeze-drying cycle via design space approach: a case study on vaccines. Pharm. Dev. Technol. 25, 1302\u20131313 (2020).","journal-title":"Pharm. Dev. Technol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00740-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00740-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00740-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T13:45:39Z","timestamp":1737207939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00740-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00740-x","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are or were at the time of the study, employees of the GSK group of companies and may hold shares in GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}